Clinical Observation of Translating to Small Cell Lung Cancer Following Treatment with EGFR-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma

Clinical Observation of Translating to Small Cell Lung Cancer Following Treatment with EGFR-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma

In recent years, the chemotherapy of non-small cell lung cancer (NSCLC) has almost been reached a platform stage, and there is no obvious progress in terms of response rate (RR) and overall survival (OS); With the great development of molecular biology, epidermal growth factor receptor-tyrosine kina...

Full description

Bibliographic Details
Main Authors: Shuping XUE, Tingting YU, Yan ZHANG, Li SHAN
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2015-10-01
Series:Chinese Journal of Lung Cancer
Subjects:
Lung neoplsms
EGFR mutation
Resistance
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2015.10.10
id doaj-e4cdb014434a45989bd7bf766f0163f3
record_format Article
spelling doaj-e4cdb014434a45989bd7bf766f0163f32020-11-25T00:52:30ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872015-10-01181065666010.3779/j.issn.1009-3419.2015.10.10Clinical Observation of Translating to Small Cell Lung Cancer Following Treatment with EGFR-Tyrosine Kinase Inhibitors in Lung AdenocarcinomaShuping XUE0Tingting YU1Yan ZHANG2Li SHAN3The First Department of Lung Cancer, Xinjiang Tumor Hospital, Urimuqi 830000, ChinaThe First Department of Lung Cancer, Xinjiang Tumor Hospital, Urimuqi 830000, ChinaThe First Department of Lung Cancer, Xinjiang Tumor Hospital, Urimuqi 830000, ChinaThe First Department of Lung Cancer, Xinjiang Tumor Hospital, Urimuqi 830000, ChinaIn recent years, the chemotherapy of non-small cell lung cancer (NSCLC) has almost been reached a platform stage, and there is no obvious progress in terms of response rate (RR) and overall survival (OS); With the great development of molecular biology, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) has good therapeutic effect on the NSCLC. But, almost all patients of EGFR-mutant lung cancers develop drug resistance to these agents. This paper reported a case of a 49-year-old woman with lung adenocarcinoma who had EGFR mutant (19-DEL) treated with EGFR-TKIs. After disease progression, histological examination of a secondary biopsy specimen revealed small cell lung cancer (SCLC) had transformed to SCLC treatment. Through the analysis of the process and effect of her therapy, the following is a summary of the relevant mechanism.http://dx.doi.org/10.3779/j.issn.1009-3419.2015.10.10Lung neoplsmsEGFR mutationResistance
collection DOAJ
language zho
format Article
sources DOAJ
author Shuping XUE
Tingting YU
Yan ZHANG
Li SHAN
spellingShingle Shuping XUE
Tingting YU
Yan ZHANG
Li SHAN
Clinical Observation of Translating to Small Cell Lung Cancer Following Treatment with EGFR-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma
Chinese Journal of Lung Cancer
Lung neoplsms
EGFR mutation
Resistance
author_facet Shuping XUE
Tingting YU
Yan ZHANG
Li SHAN
author_sort Shuping XUE
title Clinical Observation of Translating to Small Cell Lung Cancer Following Treatment with EGFR-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma
title_short Clinical Observation of Translating to Small Cell Lung Cancer Following Treatment with EGFR-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma
title_full Clinical Observation of Translating to Small Cell Lung Cancer Following Treatment with EGFR-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma
title_fullStr Clinical Observation of Translating to Small Cell Lung Cancer Following Treatment with EGFR-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma
title_full_unstemmed Clinical Observation of Translating to Small Cell Lung Cancer Following Treatment with EGFR-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma
title_sort clinical observation of translating to small cell lung cancer following treatment with egfr-tyrosine kinase inhibitors in lung adenocarcinoma
publisher Chinese Anti-Cancer Association; Chinese Antituberculosis Association
series Chinese Journal of Lung Cancer
issn 1009-3419
1999-6187
publishDate 2015-10-01
description In recent years, the chemotherapy of non-small cell lung cancer (NSCLC) has almost been reached a platform stage, and there is no obvious progress in terms of response rate (RR) and overall survival (OS); With the great development of molecular biology, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) has good therapeutic effect on the NSCLC. But, almost all patients of EGFR-mutant lung cancers develop drug resistance to these agents. This paper reported a case of a 49-year-old woman with lung adenocarcinoma who had EGFR mutant (19-DEL) treated with EGFR-TKIs. After disease progression, histological examination of a secondary biopsy specimen revealed small cell lung cancer (SCLC) had transformed to SCLC treatment. Through the analysis of the process and effect of her therapy, the following is a summary of the relevant mechanism.
topic Lung neoplsms
EGFR mutation
Resistance
url http://dx.doi.org/10.3779/j.issn.1009-3419.2015.10.10
work_keys_str_mv AT shupingxue clinicalobservationoftranslatingtosmallcelllungcancerfollowingtreatmentwithegfrtyrosinekinaseinhibitorsinlungadenocarcinoma
AT tingtingyu clinicalobservationoftranslatingtosmallcelllungcancerfollowingtreatmentwithegfrtyrosinekinaseinhibitorsinlungadenocarcinoma
AT yanzhang clinicalobservationoftranslatingtosmallcelllungcancerfollowingtreatmentwithegfrtyrosinekinaseinhibitorsinlungadenocarcinoma
AT lishan clinicalobservationoftranslatingtosmallcelllungcancerfollowingtreatmentwithegfrtyrosinekinaseinhibitorsinlungadenocarcinoma
_version_ 1725242144331923456

Similar Items